Lolamicin is an experimental antibiotic.[1] It targets Gram-negative bacteria without significantly affecting typical gut microbes.[2] Lolamicin was discovered by a team led by Paul Hergenrother at the University of Illinois Urbana-Champaign and was first reported in 2024.[1]
| |
| Identifiers | |
|---|---|
3D model (JSmol)
|
|
PubChem CID
|
|
| |
| |
| Properties | |
| C24H20N4O | |
| Molar mass | 380.451 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
In a mouse model of bacterial infection, lolamicin was found to be especially effective against Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae.[3]
Lolamicin works by interfering with the lipoprotein transport system of Gram-negative bacteria.[1]
References
edit- ^ a b c Muñoz, Kristen A.; Ulrich, Rebecca J.; Vasan, Archit K.; Sinclair, Matt; Wen, Po-Chao; Holmes, Jessica R.; Lee, Hyang Yeon; Hung, Chien-Che; Fields, Christopher J.; Tajkhorshid, Emad; Lau, Gee W.; Hergenrother, Paul J. (2024). "A Gram-negative-selective antibiotic that spares the gut microbiome". Nature. 630 (8016): 429–436. doi:10.1038/s41586-024-07502-0. PMID 38811738.
- ^ "'Smart' antibiotic can kill deadly bacteria while sparing the microbiome". nature.com. May 29, 2024.
- ^ "New antibiotic targets only gram-negative bacteria, sparing the gut". Chemical & Engineering News. June 1, 2024.